Orbimed Advisors LLC Uni Qure N.V. Transaction History

Orbimed Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $4.03 Million - $5.93 Million	-716,555 Reduced 34.71%	1,347,900 $9.13 Million
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $5.93 Million - $7.31 Million	316,900 Added 18.13%	2,064,455 $41.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $2.73 Million - $4.11 Million	150,555 Added 9.43%	1,747,555 $39.6 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $12.3 Million - $18.4 Million	722,151 Added 82.55%	1,597,000 $30 Million
Q2 2022 Aug 15, 2022	SELL	$13.15 - $20.45 $583,860 - $907,980	-44,400 Reduced 4.83%	874,849 $16.3 Million
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $4.85 Million - $7.17 Million	333,675 Added 56.98%	919,249 $16.6 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $2.98 Million - $4.37 Million	114,400 Added 24.28%	585,574 $18.7 Million
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $14.9 Million - $18.5 Million	-497,905 Reduced 51.38%	471,174 $14.5 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $671,394 - $1.01 Million	-14,900 Reduced 1.51%	969,079 $43.7 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $3.91 Million - $7.23 Million	-97,786 Reduced 9.04%	983,979 $46.7 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $8.99 Million - $18.1 Million	242,165 Added 28.84%	1,081,765 $77.5 Million
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $2.29 Million - $4.47 Million	-58,200 Reduced 6.48%	839,600 $33 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $47.4 Million - $73.8 Million	897,800 New	897,800 $70.2 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.